Comprehensive Financial Consultants Institutional Inc. Increases Stake in DexCom, Inc. $DXCM

Comprehensive Financial Consultants Institutional Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM) by 67.0% during the second quarter, HoldingsChannel reports. The firm owned 21,082 shares of the medical device company’s stock after purchasing an additional 8,458 shares during the period. Comprehensive Financial Consultants Institutional Inc.’s holdings in DexCom were worth $1,840,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock valued at $3,240,763,000 after purchasing an additional 925,882 shares in the last quarter. Jennison Associates LLC lifted its holdings in DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after purchasing an additional 2,879,489 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares in the last quarter. Nuveen LLC purchased a new position in DexCom in the 1st quarter valued at $554,893,000. Finally, Raymond James Financial Inc. lifted its holdings in DexCom by 21.8% in the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock valued at $229,117,000 after purchasing an additional 601,088 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on DXCM. Barclays raised their price objective on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Raymond James Financial raised their target price on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. The Goldman Sachs Group cut their target price on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. Oppenheimer downgraded DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Finally, Robert W. Baird cut their target price on DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a research note on Friday, September 26th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.32.

Insiders Place Their Bets

In related news, Director Mark G. Foletta sold 2,750 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 in the last three months. 0.32% of the stock is owned by company insiders.

DexCom Stock Performance

NASDAQ DXCM opened at $67.05 on Monday. The company has a market cap of $26.29 billion, a P/E ratio of 46.56, a P/E/G ratio of 1.41 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The stock has a 50-day moving average of $76.31 and a two-hundred day moving average of $77.93. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.